Northwestern Medicine and University of Wisconsin-Madison (UW) scientists have identified a gene that causes severe glaucoma in children.
Uncategorized
BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that Cell Cure has been awarded a new grant for 2016 of 8.4 million shekels (approximately $2.2 million) from the Israel Innovation Authority (“IIA,” formerly the Office of the Chief Scientist) of the Ministry of Economy and Industry. The
Uncategorized
Glaukos reports 57% increase in net sales in first quarter
Glaukos reported net sales of $23.1 million in the first quarter, a 57% increase from $14.7 million in the same quarter of 2015, according to a press release. The growth was attributed to increased use of the iStent among a growing customer base.
Uncategorized
Global Retinal Vein Occlusion Pipeline Report 2016 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Retinal Vein Occlusion – Pipeline Review, H1 2016” report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein…
Uncategorized
Global Macular Edema Pipeline Report 2016 – Review of 13 Companies & Drug Profiles – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Macular Edema – Pipeline Review, H1 2016” report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, comple…
Cancer drugs could target autoimmune diseases
Drugs currently being trialled in cancer patients have been used to successfully target an autoimmune condition in mice at UCL and King’s College London.